Hormonal
Roux-en-Y gastric bypass (RYGB) induces remission of type 2 diabetes (T2DM) in patients with BMI 30-35 kg/m2, independent of significant weight loss, by altering gastrointestinal hormone secretion (GLP-1, GIP, GLP-2).
If you have type 2 diabetes and a BMI between 30 and 35, gastric bypass surgery can put your diabetes into remission in most cases, often before you lose significant weight. This happens because the surgery changes gut hormones (GLP-1, GIP) that regulate blood sugar. Current guidelines often block access based on BMI, but evidence suggests you should be evaluated for surgery if your diabetes is difficult to control, regardless of your weight. Early intervention yields better results.
Long-term remission occurred in 88% of the patients... Weight loss failed to correlate with diabetes remission, suggesting an alternative method for diabetes resolution... The indices for both the RYGB and SG had similar insulin and glucagon secretion; the GLP-1, GLP-2, and GIP response increased in both surgical groups.
Why this rating
Based on randomized controlled trials (Cohen, Ikramuddin) and long-term observational data (SOS study), though some studies have small sample sizes or short follow-up.
Source
Metabolic Surgery Is No Longer Just Bariatric Surgery
Elizabeth C. Moore et al. · Diabetes Technology & Therapeutics · 2014
DOI 10.1089/dia.2014.1509
More from this paper
- Bariatric surgery prevents the onset of type 2 diabetes in obese patients without preexisting diabetes, with incidence rates significantly lower than non-surgical obese controls.Good
- Preoperative factors such as duration of diabetes, high HbA1c, and insulin use predict failure of T2DM remission after bariatric surgery.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →